

| (R)-3-Acetoxy-4-(trimethylammonio)butyrate Hydrochloride |
| R-(-)-2-Acetyloxy-3-carboxy-N,N,N-trimethyl-1-propanaminium chloride |
| ALC |
| ALCAR |
¡Ø ÈÇиí : O-Acetyl-L-carnitine HCl, 98% (HPLC)
¡Ø µî±Þ : Amino Acids > Unnatural Amino Acids
APIs and Bioactives > AChR Agonists
¡Ø ÆÇ¸Å Æ÷Àå´ÜÀ§ : 1g , 5g , 25g
¡Ø ÈÇÐ½Ä : C9H17NO4.HCl
¡Ø CAS # : [5080-50-2]
|
| IDENTITY |
|
| CAS Registry #: |
[5080-50-2] |
| MDL Number: |
MFCD00082230 |
| MF: |
C9H17NO4.HCl |
| MW: |
239.6965 |
| BRN: |
4340103 | |
| SPECIFICATIONS & PROPERTIES |
|
| Purity: |
98% (HPLC) |
| Available Spectra: |
LCMS, HPLC, Polarimetry |
| Physical Form: |
White to off-white crystalline powder or powder |
| Melting Point: |
194-202¡ÆC |
| Optical Rotation: |
-26.0¡Æ - -31.0¡Æ (c=1, H2O) |
| Long-Term Storage: |
Store long-term at 2-8¡ÆC |
| Shipping: |
Not Regulated for Shipping | | |
BIOLOGICAL INFO |
|
| Form: |
HCl salt |
REVIEWAcetyl-L-carnitine or ALCAR, is an acetylated form of L-carnitine (a betaine derivative of beta-hydroxybutyrate, is found in virtually all cells of higher animals and also in some microorganisms and plants. In animals it is synthesized almost exclusively in the liver). Acetylcarnitine is broken down in the blood by plasma esterases to carnitine which is used by the body to transport fatty acids into the mitochondria for breakdown. During strenuous exercise, a large portion of L-carnitine and unused acetyl-CoA are converted to ALCAR and CoA inside mitochondria by carnitine O-acetyltransferase.The ALCAR is transported outside the mitochondria where it converts back to the two constituents. The L-carnitine is cycled back into the mitochondria with acyl groups to facilitate fatty acid utilization, but excess acetyl-CoA may block it.Excess acetyl-CoA causes more carbohydrates to be used for energy at the expense of fatty acids. This occurs by different mechanisms inside and outside the mitochondria. ALCAR transport decreases acetyl-CoA inside the mitochondria, but increases it outside.Glucose metabolism in diabetics improves with administration of either ALCAR or L-carnitine.] ALCAR decreases glucose consumption in favor of fat oxidation in non-diabetics. A portion of L-carnitine is converted to ALCAR after ingestion in humans. ALC represents a compound of great interest for its wide clinical application in various neurological disorders: it may be of benefit in treating Alzheimers dementia, depression in the elderly, HIV infection, chronic fatigue syndrome, peripheral neuropathies, ischemia and reperfusion of the brain, and cognitive impairment associated with various conditions. Acetyl-L-carnitine is also used as a dietary supplement as a more orally available precursor to L-carnitine in regards to carbohydrate and fat metabolism.
REFERENCES
[1] |
Malaguarnera M. Carnitine derivatives: clinical usefulness. Curr Opin Gastroenterol. 2012 Mar;28(2):166-76. |
| [2] |
Mingorance C, Rodr?guez-Rodr?guez R, Justo ML, Alvarez de Sotomayor M, Herrera MD, Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vasc Health Risk Manag. 2011;7:169-76. |
| [3] |
[No authors listed] Acetyl-L-carnitine. Monograph. Altern Med Rev. 2010 Apr;15(1):76-83. |
| [4] |
Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev. 2009 Nov 30;61(14):1332-42. |
Risk Description(s)
| R36/37/38: |
Irritating to eyes, respiratory system and skin |
Safety Description(s)
| S26: |
In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| S37/39: |
Wear suitable gloves and eye/face protection. |


°í¾×°áÁ¦ÀÇ °æ¿ì ¾ÈÀüÀ» À§ÇØ Ä«µå»ç¿¡¼ È®ÀÎÀüȸ¦ µå¸± ¼öµµ ÀÖ½À´Ï´Ù. È®ÀΰúÁ¤¿¡¼ µµ³ Ä«µåÀÇ »ç¿ëÀ̳ª ŸÀÎ ¸íÀÇÀÇ ÁÖ¹®µî Á¤»óÀûÀÎ ÁÖ¹®ÀÌ ¾Æ´Ï¶ó°í ÆÇ´ÜµÉ °æ¿ì ÀÓÀÇ·Î ÁÖ¹®À» º¸·ù ¶Ç´Â Ãë¼ÒÇÒ ¼ö ÀÖ½À´Ï´Ù.
¹«ÅëÀå ÀÔ±ÝÀº »óǰ ±¸¸Å ´ë±ÝÀº PC¹ðÅ·, ÀÎÅͳݹðÅ·, ÅÚ·¹¹ðÅ· ȤÀº °¡±î¿î ÀºÇà¿¡¼ Á÷Á¢ ÀÔ±ÝÇÏ½Ã¸é µË´Ï´Ù.
ÁÖ¹®½Ã ÀÔ·ÂÇÑ ÀÔ±ÝÀÚ¸í°ú ½ÇÁ¦ÀÔ±ÝÀÚÀÇ ¼º¸íÀÌ ¹Ýµå½Ã ÀÏÄ¡ÇÏ¿©¾ß Çϸç, 7ÀÏ À̳»·Î ÀÔ±ÝÀ» ÇÏ¼Å¾ß Çϸç ÀԱݵÇÁö ¾ÊÀº ÁÖ¹®Àº ÀÚµ¿Ãë¼Ò µË´Ï´Ù.
¹è¼Û ¹æ¹ý : ÅÃ¹è ¹× Á÷³³
¹è¼Û Áö¿ª : Àü±¹
¹è¼Û ºñ¿ë : ÃÑ ±¸¸Å ºñ¿ëÀÌ £Ü100,000 (VATº°µµ) ¹Ì¸¸ÀÏ °æ¿ì ÂøºÒ·Î ¹ß¼Û
¹è¼Û ±â°£ : ±¹»êǰ (3~7ÀÏ), ¼öÀÔǰ (7~14ÀÏ)
¹è¼Û ¾È³»
- »ê°£º®Áö³ª µµ¼Áö¹æÀº º°µµÀÇ Ãß°¡±Ý¾×À» ÁöºÒÇÏ¼Å¾ß ÇÏ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù.
°í°´´Ô²²¼ ÁÖ¹®ÇϽŠ»óǰÀº ÀÔ±Ý È®ÀÎÈÄ ¹è¼ÛÇØ µå¸³´Ï´Ù. ´Ù¸¸, »óǰÁ¾·ù¿¡ µû¶ó¼ »óǰÀÇ ¹è¼ÛÀÌ ´Ù¼Ò Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù.


±³È¯ ¹× ¹ÝǰÀÌ °¡´ÉÇÑ °æ¿ì
- »óǰÀ» °ø±Þ ¹ÞÀ¸½Å ³¯·ÎºÎÅÍ 7ÀÏÀ̳»
±³È¯ ¹× ¹ÝǰÀÌ ºÒ°¡´ÉÇÑ °æ¿ì
- °í°´´ÔÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óǰµîÀÌ ¸ê½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
- Æ÷ÀåÀ» °³ºÀÇÏ¿´°Å³ª Æ÷ÀåÀÌ ÈÑ¼ÕµÇ¾î »óǰ°¡Ä¡°¡ »ó½ÇµÈ °æ¿ì
- ½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇÏ¿© ÀçÆÇ¸Å°¡ °ï¶õÇÒ Á¤µµ·Î »óǰµîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
- ¿Âµµ°ü¸®Ç° ¹× ¼öÀÔǰÀº ¹ÝǰÀÌ ºÒ°¡´ÉÇÕ´Ï´Ù.
¡Ø ÁÖ¹® Ãë¼Ò ¹× ¹ÝǰÀ¸·Î ȯºÒÀ» ¿äûÇÏ½Ç °æ¿ì¿¡´Â E-mail(info@syinnovation.co.kr) »ó´ã¼ºñ½º³ª °í°´¸¸Á·¼¾ÅÍ(070-4829-4101)¸¦ ÅëÇØ ¿äûÇϽøé Ä£ÀýÇÏ°Ô Ã³¸®ÇØ µå¸®°Ú½À´Ï´Ù.